BCRX

7.06

0.43% 0.03

Handel nachbörslich: 6.99 -0.07 -0.99%

Biocryst Pharmaceuticals Inc (BCRX)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt BCRX? Forum Prognose

Schlusskurs vom Vortag:

$7.03

Offen:

$7.05

24-Stunden-Volumen:

1.68M

Relative Volume:

0.88

Marktkapitalisierung:

$1.46B

Einnahmen:

$331.41M

Nettoeinkommen (Verlust:

$-226.54M

KGV:

-5.648

EPS:

-1.25

Netto-Cashflow:

$-97.31M

1W Leistung:

-13.80%

1M Leistung:

-7.35%

6M Leistung:

+12.42%

1J Leistung:

+31.96%

1-Tages-Spanne:

$6.92

$7.135

1-Wochen-Bereich:

$6.92

$8.24

52-Wochen-Spanne:

$4.03

$8.88

Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile

Firmenname

Biocryst Pharmaceuticals Inc

Sektor

Healthcare (1196)

Branche

Biotechnology (683)

Telefon

919-859-1302

Adresse

4505 EMPEROR BOULEVARD, DURHAM, NC

Mitarbeiter

531

Twitter

@biocrystpharma

Nächster Verdiensttermin

2024-11-04

Neueste SEC-Einreichungen

BCRX's Discussions on Twitter

Vergleichen Sie BCRX mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
BCRX	7.06	1.46B	331.41M	-226.54M	-97.31M	-1.25
VRTX	467.01	119.87B	10.63B	-479.80M	-1.35B	13.33
REGN	762.00	83.27B	13.85B	4.65B	3.32B	35.06
ARGX	567.90	33.96B	1.86B	-40.29M	-1.28B	-4.16
ALNY	232.27	30.18B	2.09B	-332.26M	16.06M	-4.14
BNTX	101.87	24.42B	3.30B	-501.07M	1.03B	11.54

Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2023-09-18	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2023-08-04	Hochstufung	Jefferies	Hold → Buy
2023-07-13	Hochstufung	BofA Securities	Neutral → Buy
2023-02-22	Hochstufung	Needham	Hold → Buy
2022-11-02	Hochstufung	Evercore ISI	In-line → Outperform
2022-08-05	Herabstufung	Evercore ISI	Outperform → In-line
2022-08-05	Herabstufung	Oppenheimer	Outperform → Perform
2022-04-18	Herabstufung	Barclays	Overweight → Equal Weight
2022-04-11	Herabstufung	BofA Securities	Buy → Neutral
2021-12-10	Eingeleitet	Oppenheimer	Outperform
2021-08-06	Herabstufung	Jefferies	Buy → Hold
2021-08-03	Eingeleitet	Cantor Fitzgerald	Overweight
2021-03-01	Eingeleitet	Cowen	Outperform
2020-09-29	Fortgesetzt	JP Morgan	Overweight
2020-06-17	Eingeleitet	BTIG Research	Neutral
2020-05-05	Hochstufung	Barclays	Equal Weight → Overweight
2019-11-15	Hochstufung	BofA/Merrill	Neutral → Buy
2019-05-24	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2018-11-16	Fortgesetzt	Piper Jaffray	Overweight
2018-08-08	Fortgesetzt	JP Morgan	Overweight
2018-07-17	Hochstufung	BofA/Merrill	Underperform → Neutral
2018-06-22	Eingeleitet	Seaport Global Securities	Neutral
2018-01-02	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2017-12-20	Eingeleitet	Barclays	Equal Weight
2017-09-15	Eingeleitet	RBC Capital Mkts	Sector Perform
2017-09-06	Hochstufung	JP Morgan	Neutral → Overweight
2017-09-06	Hochstufung	Jefferies	Hold → Buy
2017-02-16	Eingeleitet	Ladenburg Thalmann	Buy
2016-08-12	Hochstufung	Piper Jaffray	Neutral → Overweight
2016-08-04	Herabstufung	JMP Securities	Mkt Outperform → Mkt Perform
2016-02-09	Bestätigt	FBR Capital	Outperform
2016-02-09	Herabstufung	JP Morgan	Overweight → Neutral
2016-02-09	Herabstufung	Needham	Buy → Hold

Alle ansehen

Biocryst Pharmaceuticals Inc Aktie (BCRX) Neueste Nachrichten

09:53 AM

Primary Hyperoxaluria Drug Market SWOT Analysis by Leading Key Players: Pfizer, Novartis, BioCryst - openPR

09:53 AM

07:26 AM

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Sees Large Drop in Short Interest - MarketBeat

07:26 AM

02:01 AM

BioCryst Launches ORLADEYO® (berotralstat) in Ireland - GlobeNewswire

02:01 AM

02:00 AM

BioCryst's ORLADEYO Becomes First Oral HAE Treatment Approved in Ireland | BCRX Stock News - StockTitan

02:00 AM

Nov 17, 2024

(BCRX) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Nov 17, 2024

Nov 13, 2024

Avian influenza Treatment Market Growth Trends: Regional - openPR

Nov 13, 2024

Nov 12, 2024

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Sold by GSA Capital Partners LLP - MarketBeat

Nov 12, 2024

Nov 09, 2024

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat

Nov 09, 2024

Nov 07, 2024

Vanguard Group Inc's Strategic Acquisition in BioCryst Pharmaceu - GuruFocus.com

Nov 07, 2024

HC Wainwright Has Optimistic Outlook of BCRX Q4 Earnings - MarketBeat

Nov 07, 2024

Nov 06, 2024

Ionis Looks Ahead To Commercializing Its Own Products - Citeline News & Insights

Nov 06, 2024

Objective long/short (BCRX) Report - Stock Traders Daily

Nov 06, 2024

BioCryst to Present at Upcoming Investor Conferences - GlobeNewswire

Nov 06, 2024

BioCryst (BCRX) to Present at Three Major Healthcare Investor Conferences | BCRX Stock News - StockTitan

Nov 06, 2024

Nov 05, 2024

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Nov 05, 2024

BioCryst Pharmaceuticals (NASDAQ:BCRX) Posts Earnings Results, Hits Estimates - MarketBeat

Nov 05, 2024

BioCryst Pharmaceuticals' (BCRX) "Outperform" Rating Reiterated at Royal Bank of Canada - MarketBeat

Nov 05, 2024

Barclays Forecasts Strong Price Appreciation for BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock - MarketBeat

Nov 05, 2024

BCRXBioCryst Pharmaceuticals Inc Latest Stock News & Market Updates - StockTitan

Nov 05, 2024

Earnings call: BioCryst Pharmaceuticals reports strong Q3 growth - Investing.com India

Nov 05, 2024

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 05, 2024

BioCryst Announces Strong Q3 2024 Revenue Growth - Yahoo Finance

Nov 05, 2024

BioCryst Pharmaceuticals, Inc. Provides Financial Guidance for the Year 2024, Second Half of 2025 and Full Year of 2026 - Marketscreener.com

Nov 05, 2024

BioCryst Awards Key Talent with $8.01 Stock Options, RSU Compensation Package | BCRX Stock News - StockTitan

Nov 05, 2024

BioCryst Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St

Nov 05, 2024